MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (651)	2/11/1998 5:36:00 PM
From: David Cathcart	Read Replies (2) of 1826

V1, Here is the Q3 1997 news release: dljdirect.com However, they did not breakout Salagen sales specifically in that release. In today's conference call, they mentioned that they see the total market for Salagen for head & neck at $10M - $12M annually. They estimate 20% of current Salagen sales are going to off-label use. With the Q4 1997 Salagen sales at $2.5M, or $10M annualized, they are beginning to approach the estimated total market, and it stands to reason that incremental sales increases should taper off. Once Salagen is approved for Sjogren's, there will be a much bigger market to pursue. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next